Harrow Health (NASDAQ:HROW) Announces Earnings Results, Misses Estimates By $0.03 EPS

Harrow Health (NASDAQ:HROW) announced its earnings results on Wednesday. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.03), Fidelity Earnings reports. Harrow Health had a return on equity of 100.84% and a net margin of 65.84%. The firm had revenue of $13.52 million for the quarter, compared to the consensus estimate of $12.55 million.

HROW traded down $1.49 during midday trading on Thursday, hitting $4.91. The company had a trading volume of 67,244 shares, compared to its average volume of 253,168. Harrow Health has a 52 week low of $2.22 and a 52 week high of $8.99. The company has a quick ratio of 3.22, a current ratio of 3.43 and a debt-to-equity ratio of 0.47. The stock has a market cap of $157.36 million, a P/E ratio of 8.02 and a beta of 0.06. The stock’s 50 day simple moving average is $7.66.

A number of equities analysts recently weighed in on the stock. TheStreet raised shares of Harrow Health from a “d-” rating to a “c” rating in a research note on Wednesday, May 1st. Zacks Investment Research downgraded shares of Harrow Health from a “buy” rating to a “hold” rating in a research note on Wednesday, May 15th. Finally, ValuEngine downgraded shares of Harrow Health from a “hold” rating to a “sell” rating in a research note on Monday.

In other Harrow Health news, Director Robert J. Kammer sold 10,000 shares of Harrow Health stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $5.78, for a total value of $57,800.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Robert J. Kammer sold 6,500 shares of Harrow Health stock in a transaction on Monday, July 15th. The shares were sold at an average price of $7.91, for a total transaction of $51,415.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 23,000 shares of company stock valued at $154,000. Insiders own 12.43% of the company’s stock.

Harrow Health Company Profile

Harrow Health, Inc owns a portfolio of healthcare businesses, primarily ophthalmology pharmaceutical compounding business, ImprimisRx, in the United States. It develops, produces, and sells medications, including ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications to physicians and patients.

Recommended Story: Stock Symbol

Earnings History for Harrow Health (NASDAQ:HROW)

Receive News & Ratings for Harrow Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow Health and related companies with MarketBeat.com's FREE daily email newsletter.